Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2022 1
2023 1
2024 2
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases.
Behlke LM, Lenze EJ, Carney RM. Behlke LM, et al. CNS Drugs. 2020 Nov;34(11):1133-1147. doi: 10.1007/s40263-020-00763-z. CNS Drugs. 2020. PMID: 33064291 Free PMC article. Review.
Twelve novel non-selective serotonin reuptake inhibitor antidepressants were identified from the literature: venlafaxine, desvenlafaxine, duloxetine, milnacipran, levomilnacipran, mirtazapine, bupropion, vilazodone, vortioxetine, agomelatine, moclobemide, and ketamine-esketami …
Twelve novel non-selective serotonin reuptake inhibitor antidepressants were identified from the literature: venlafaxine, desvenlafaxine, du …
Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial.
Conway CR, Aaronson ST, Sackeim HA, George MS, Zajecka J, Bunker MT, Duffy W, Stedman M, Riva-Posse P, Allen RM, Quevedo J, Berger M, Alva G, Malik MA, Dunner DL, Cichowicz I, Banov M, Manu L, Nahas Z, Macaluso M, Mickey BJ, Sheline Y, Kriedt CL, Lee YL, Gordon C, Shy O, Tran Q, Yates L, Rush AJ. Conway CR, et al. Brain Stimul. 2025 May-Jun;18(3):676-689. doi: 10.1016/j.brs.2024.12.1191. Epub 2024 Dec 18. Brain Stimul. 2025. PMID: 39706521 Free article. Clinical Trial.
Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial report.
Conway CR, Aaronson ST, Sackeim HA, Duffy W, Stedman M, Quevedo J, Allen RM, Riva-Posse P, Berger MA, Alva G, Malik MA, Dunner DL, Cichowicz I, Luing H, Zajecka J, Nahas Z, Mickey BJ, Kablinger AS, Kriedt CL, Bunker MT, Lee YL, Shy O, Majewski S, Olin B, Tran Q, Rush AJ. Conway CR, et al. Brain Stimul. 2024 Mar-Apr;17(2):448-459. doi: 10.1016/j.brs.2024.03.016. Epub 2024 Apr 2. Brain Stimul. 2024. PMID: 38574853 Free article. Clinical Trial.
OBJECTIVE: To describe pre-implantation baseline clinical characteristics and treatment history of patients with unipolar, major depressive disorder (MDD), overall and as a function of exposure to interventional psychiatric treatments (INTs), including electroconvulsive therapy, …
OBJECTIVE: To describe pre-implantation baseline clinical characteristics and treatment history of patients with unipolar, major depressive …
Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report.
Conway CR, Rush AJ, Aaronson ST, Bunker MT, Gordon C, George MS, Riva-Posse P, Allen RM, Nahas Z, Kriedt CL, Zajecka J, Dunner DL, Quevedo J, Sheline Y, Duffy W, Mickey BJ, Stedman M, Alva G, Manu L, Tran Q, Zorumski CF, Macaluso M, Banov M, Cusin C, Bennett JI, Brown H, Way J, Shy O, Lee YL, McAllister-Williams RH, McIntyre RS, Sackeim HA. Conway CR, et al. Int J Neuropsychopharmacol. 2026 Jan 6;29(1):pyaf080. doi: 10.1093/ijnp/pyaf080. Int J Neuropsychopharmacol. 2026. PMID: 41529263 Free PMC article. Clinical Trial.
INTERVENTIONS: Vagus nerve stimulation and concomitant psychotropic medications and interventional psychiatric modalities (electroconvulsive therapy, transcranial magnetic stimulation, and ketamine/esketamine) were characterized over the 12-month extension. MAIN OUTCOMES A …
INTERVENTIONS: Vagus nerve stimulation and concomitant psychotropic medications and interventional psychiatric modalities (electroconvulsive …
Role of trazodone in treatment of major depressive disorder: an update.
Fagiolini A, González-Pinto A, Miskowiak KW, Morgado P, Young AH, Vieta E. Fagiolini A, et al. Ann Gen Psychiatry. 2023 Sep 2;22(1):32. doi: 10.1186/s12991-023-00465-y. Ann Gen Psychiatry. 2023. PMID: 37660092 Free PMC article. Review.
It has minimal anticholinergic activity but may be associated infrequently with orthostatic hypotension (especially in patients with cardiovascular disease or older adults), QT interval prolongation, cardiac arrhythmias, and rare episodes of priapism. The low liability for …
It has minimal anticholinergic activity but may be associated infrequently with orthostatic hypotension (especially in patients with cardiov …
Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program.
Doherty T, Wajs E, Melkote R, Miller J, Singh JB, Weber MA. Doherty T, et al. CNS Drugs. 2020 Mar;34(3):299-310. doi: 10.1007/s40263-020-00699-4. CNS Drugs. 2020. PMID: 31994024 Free PMC article.
Effects on cardiac repolarization were assessed in a phase I randomized, positive- and active-controlled thorough corrected QT (QTc) interval study. For adverse events, odds ratio (OR) [95% confidence interval] for esketamine/antidepressant versus antidepressant/pla …
Effects on cardiac repolarization were assessed in a phase I randomized, positive- and active-controlled thorough corrected QT (QTc) …
Effects of different dosages esketamine on cardiac conduction and heterogeneity of Cx43: the epicardial mapping in guinea pigs.
Cao Y, Song Y, Wang Z, Tang J, Yi J, Liu Y, An L, Pan Z, Gao H. Cao Y, et al. Ann Transl Med. 2022 Jul;10(14):772. doi: 10.21037/atm-22-2614. Ann Transl Med. 2022. PMID: 35965820 Free PMC article.
This study sought to evaluate the cardiac safety of esketamine at 3 sub-anesthetic gradient concentrations. METHODS: We examined the cardiac electrophysiological effects of esketamine with infusion rates of 0.125, 0.25, and 0.5 mg.kg(-1).h(-1). ...CONCLUSIONS: These …
This study sought to evaluate the cardiac safety of esketamine at 3 sub-anesthetic gradient concentrations. METHODS: We examined the …